Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gamida Cell Ltd (NQ: GMDA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gamida Cell Ltd

< Previous 1 2 3 4 5 6 7 Next >
Why Is Gamida Cell (GMDA) Stock Up 48% Today?
Gamida Cell (GMDA) stock is taking off on Tuesday after getting an update from the FDA concerning cell therapy Omisirge. 
Via InvestorPlace
Why Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket
Gainers Super League Gaming, Inc. (NASDAQ: SLGG) jumped 119.8% to $0.9408 in pre-market trading. LandVault and Super League disclosed a strategic partnership to provide brands with scalable solutions... 
Via Benzinga
Promising Upsides on these Biotech Penny Stocks
These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration. 
Via MarketBeat
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a look at the biggest pre-market stock movers traders will want to keep an eye on Tuesday! 
Via InvestorPlace
Gamida Cell Scores FDA Nod For Cord Blood-Based Cancer Therapy
Via Benzinga
Earnings Outlook For Gamida Cell
Via Benzinga
Earnings Preview: Gamida Cell
Via Benzinga
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
From Gamida Cell Ltd.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! 
Via InvestorPlace
Earnings Scheduled For March 27, 2023
Companies Reporting Before The Bell • Viomi Technology Co (NASDAQ:VIOT) is likely to report earnings for its fourth quarter. • Vislink Technologies (NASDAQ:VISL) is projected to report earnings for its... 
Via Benzinga
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Changes to Board of Directors
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Why Adial Pharmaceuticals Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
From Gamida Cell Ltd.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning! 
Via InvestorPlace
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on... 
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel... 
Via Benzinga
Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million. 
Via Benzinga
Gamida Cell Provides Regulatory Update on Omidubicel
From Gamida Cell Ltd.
Via Business Wire
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt analyst Barton Crockett maintained a Neutral rating on the stock. Pinterest shares rose 2% to $24.91 in... 
Via Benzinga
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
From Gamida Cell Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback